← Evidence map

TrialJournal of Crohn's & colitis2025

Mirikizumab impact on disease clearance in patients with moderately to severely active ulcerative colitis: analysis of a pre-specified LUCENT trial endpoint.

Jean-Frederic Colombel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

3 trials

NCT03518086phase 31,281 enrolled2018 NCT03519945phase 31,058 enrolled2018 NCT03524092phase 31,328 enrolled2018

Mirikizumab impact on disease clearance in patients with moderately to severely active ulcerative colitis: analysis of a pre-specified LUCENT trial endpoint. | Socratic